NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis $44.60 -1.25 (-2.73%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$44.60 -0.01 (-0.01%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Praxis Precision Medicines Stock (NASDAQ:PRAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PRAX alerts:Sign Up Key Stats Today's Range$44.56▼$46.9350-Day Range$28.47▼$45.8552-Week Range$26.70▼$91.83Volume232,393 shsAverage Volume387,718 shsMarket Capitalization$908.46 millionP/E RatioN/ADividend YieldN/APrice Target$109.90Consensus RatingModerate Buy Company OverviewPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Read More… Praxis Precision Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScorePRAX MarketRank™: Praxis Precision Medicines scored higher than 51% of companies evaluated by MarketBeat, and ranked 546th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 9 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePraxis Precision Medicines has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Praxis Precision Medicines' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Praxis Precision Medicines are expected to decrease in the coming year, from ($10.22) to ($12.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 5.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Praxis Precision Medicines' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.88% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Praxis Precision Medicines has recently decreased by 4.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.88% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Praxis Precision Medicines has recently decreased by 4.26%, indicating that investor sentiment is improving. News and Social Media1.6 / 5News Sentiment-0.04 News SentimentPraxis Precision Medicines has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Praxis Precision Medicines this week, compared to 5 articles on an average week.Search Interest6 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Praxis Precision Medicines' insider trading history. Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAX Stock News HeadlinesFormer head trader of Denver-based investing company pleads guilty to insider tradingJune 9 at 5:01 AM | finance.yahoo.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | globenewswire.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.June 12, 2025 | Porter & Company (Ad)Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by AnalystsJune 3, 2025 | americanbankingnews.comPraxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock UpsideMay 7, 2025 | benzinga.comChardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy RecommendationMay 7, 2025 | msn.comPraxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor EventMay 5, 2025 | finance.yahoo.comPraxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)May 4, 2025 | finance.yahoo.comSee More Headlines PRAX Stock Analysis - Frequently Asked Questions How have PRAX shares performed this year? Praxis Precision Medicines' stock was trading at $76.96 at the beginning of the year. Since then, PRAX stock has decreased by 42.0% and is now trading at $44.60. View the best growth stocks for 2025 here. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its quarterly earnings results on Friday, May, 2nd. The company reported ($3.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.20) by $0.09. Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative trailing twelve-month return on equity of 54.86%. When did Praxis Precision Medicines' stock split? Praxis Precision Medicines shares reverse split on Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Praxis Precision Medicines' top institutional shareholders include Cormorant Asset Management LP (8.57%), Adage Capital Partners GP L.L.C. (8.56%), Price T Rowe Associates Inc. MD (5.38%) and Vanguard Group Inc. (5.34%). Insiders that own company stock include Alex Nemiroff, Lauren Mastrocola, Dean J Mitchell, Marcio Souza and Jill Desimone. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Praxis Precision Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Praxis Precision Medicines investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/02/2025Today6/12/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRAX CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$109.90 High Stock Price Target$270.00 Low Stock Price Target$28.00 Potential Upside/Downside+146.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($10.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$123.28 million Net Margins-9,409.22% Pretax Margin-9,409.22% Return on Equity-54.86% Return on Assets-50.52% Debt Debt-to-Equity RatioN/A Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$8.12 million Price / Sales111.85 Cash FlowN/A Price / Cash FlowN/A Book Value$7.92 per share Price / Book5.63Miscellaneous Outstanding Shares20,369,000Free Float18,135,000Market Cap$908.46 million OptionableOptionable Beta2.60 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PRAX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.